You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
ExpreS2ion Biotechnologies - What to look out for in 2024
Together with ExpreS2ion Biotechnologies CEO Bent Frandsen, we took a look at 2023's main achievements and challenges as well as the foundation this has given the company. We also touched upon 2024, focusing on what investors should look out for as the main potential achievements.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 11.45 15 February 2024.
Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025
5 forudsigelser for aktiemarkedet i 2025
Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data
Introduction to the Helsinki Stock Exchange | Company Night Dec. 16, 2024
Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
View all videos